METHOD / EDITORIAL STANDARD
Read the indication, then the evidence
An independent digest designed to keep approval language, study design, and effect estimates aligned.
What this watch monitors
FDA Peptide Watch is an independent editorial digest of four research-peptide records: semaglutide, tirzepatide, tesamorelin, and PT-141 or bremelanotide. The organizing frame is FDA approval status across peptide classes. That means the site asks a more precise question than whether a peptide is “approved.” It asks which regulated product was reviewed, for which use, in which population, and on what evidence.
The roster is deliberately varied. Two compounds act on incretin receptors and have large metabolic trial programs. One stimulates the growth-hormone axis and has a narrow HIV-associated lipodystrophy indication. One activates central melanocortin receptors and has a narrow sexual-desire indication. Placing them together exposes how easily a molecule-level label can obscure an indication-level decision.
This is a literature desk, not a clinical service or marketplace. It does not select treatments, interpret an individual history, source compounds, or turn a study protocol into instructions. Its job is to report the record accurately enough that approval, investigation, and absence of review remain distinct categories.
How the evidence is weighed
The site privileges study design and population before rhetoric. Randomized controlled trials can estimate effects against a comparator under defined conditions. Head-to-head trials address relative outcomes directly. Meta-analyses can improve precision by pooling studies, though variation among those studies still matters. Open-label extensions add longer exposure but lose blinding and concurrent placebo control. Mechanistic and animal studies can clarify biological pathways without proving a human clinical benefit.
Quantitative claims remain attached to their citations. A percentage body-weight change is not treated as interchangeable with a hazard ratio, visceral-fat area, or a symptom-scale score. Sample size and follow-up matter because estimates from a small short study carry a different evidentiary weight from those in a large outcome trial. When a result is statistically significant, the page still asks whether the endpoint and population match the claim being made.
Community reports appear only where the composed corpus contains them and are labeled anecdotal, not clinical evidence. They can surface recurring experience, but self-selection, uncertain exposure, missing denominators, and lack of controls prevent causal or frequency conclusions.
The regulatory reading rule
Every status line follows the same rule: approval attaches to a specific product and indication. Tesamorelin’s reviewed use in HIV-associated lipodystrophy does not establish general weight-loss efficacy. Bremelanotide’s reviewed use in premenopausal women with acquired, generalized hypoactive sexual desire disorder does not extend to every population. The broad semaglutide and tirzepatide portfolios still do not validate unregulated material bearing those names.
The site also keeps positive and negative findings visible together. A compound can produce a meaningful endpoint and still carry gastrointestinal, biliary, hormonal, cardiovascular, or pigmentation cautions. An animal mechanism can be compelling while a particular behavioral model is negative. An open-label extension can add useful duration while offering less control than a blinded trial.
References are aggregated on one ledger and numbered consistently across every page. Corrections are welcome through the editorial desk. The standard is quiet and testable: state what was studied, report what was found, identify the limit, and leave conclusions no broader than the evidence.